Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call

Core Insights - Celcuity Inc. will release its financial results for Q4 and full year 2025 on March 25, 2026, after market close, followed by a webcast/teleconference at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update [1] Company Overview - Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications [3] - The lead therapeutic candidate, gedatolisib, is a potent pan-PI3K and mTORC1/2 inhibitor that blocks the PI3K/AKT/mTOR pathway comprehensively [3] - Celcuity has completed enrollment for the Phase 3 clinical trial VIKTORIA-1, which evaluates gedatolisib in combination with fulvestrant, with or without palbociclib, for HR+/HER2- advanced breast cancer [3] - The ongoing Phase 3 clinical trial VIKTORIA-2 is assessing gedatolisib in combination with a CDK4/6 inhibitor and fulvestrant as first-line treatment for endocrine resistant HR+/HER2- advanced breast cancer [3] - A Phase 1/2 clinical trial, CELC-G-201, is also ongoing, evaluating gedatolisib in combination with darolutamide for metastatic castration resistant prostate cancer [3]